Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure

NCT02653482 is registered in ClinicalTrials.gov with Saint Luke's Health System as lead sponsor.

NCT NCT02653482
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02653482 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure
Lead sponsor
Saint Luke's Health System
Phase
Phase 4
Overall status
Completed
Start date
March 3, 2016
Completion date
June 28, 2019
Enrollment
263 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

chronic heart failure with reduced systolic function